导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -14.71% | 4082/4773 |
| 近一周 | -2.00% | 1050/5461 |
| 近一月 | -0.90% | 840/5420 |
| 近一季 | -8.32% | 2774/5208 |
| 近半年 | -17.51% | 4192/4919 |
| 近一年 | -2.00% | 2959/4366 |
| 近两年 | 32.48% | 2180/2954 |
| 近三年 | 1.26% | 1905/2253 |
| 成立以来 | 5.58% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.36% 3603/4961 |
-1.11% 3335/5312 |
- - |
- - |
| 2025 | 27.22% 1574/4813 |
-3.94% 3109/3635 |
11.41% 185/4076 |
7.13% 3476/4524 |
10.96% 176/4813 |
| 2024 | 4.10% 1892/3463 |
-8.33% 2221/2808 |
2.52% 343/3014 |
11.05% 2561/3129 |
-0.25% 1358/3463 |
| 2023 | -20.49% 1876/2656 |
-6.63% 2168/2280 |
1.97% 187/2385 |
-9.42% 1819/2515 |
-7.80% 2211/2655 |
| 2022 | -24.13% 1191/2207 |
-22.12% 1685/1919 |
6.26% 738/2016 |
-5.70% 85/2113 |
-2.78% 1813/2208 |
| 2021 | 18.30% 213/1822 |
-17.84% 1204/1255 |
10.69% 441/1330 |
9.96% 128/1466 |
18.30% 36/1822 |
| 2020 | 75.44% 53/1250 |
0.48% 161/1028 |
14.70% 538/1067 |
27.72% 21/1164 |
19.19% 80/1184 |
| 2019 | 23.12% 635/1092 |
28.06% 327/739 |
-8.49% 593/788 |
5.23% 158/850 |
-0.16% 886/918 |
| 2018 | -26.77% 399/834 |
- - |
-18.04% 591/631 |
2.46% 111/660 |
-13.06% 507/682 |
| 2017 | -15.94% 565/714 |
- - |
- - |
- - |
- - |
| 2016 | -21.11% 451/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 前海开源中证军工指数C VS. 长安沪深300非周期A(740101) |